Free Trial

Compare Stocks

Comparative Price Performance Over Time

Compare Stocks - Price & Volume

CompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's Volume
AnaptysBio, Inc. stock logo
ANAB
AnaptysBio
$23.47
-2.0%
$22.97
$13.36
$27.50
$641.20M-0.33328,333 shs345,381 shs
Crinetics Pharmaceuticals, Inc. stock logo
CRNX
Crinetics Pharmaceuticals
$46.28
+4.2%
$46.47
$15.76
$53.70
$3.65B0.64810,654 shs1.55 million shs
Heron Therapeutics, Inc. stock logo
HRTX
Heron Therapeutics
$3.86
+4.3%
$2.91
$0.50
$3.90
$581.51M1.812.74 million shs2.84 million shs
Kura Oncology, Inc. stock logo
KURA
Kura Oncology
$21.19
+2.8%
$20.45
$7.41
$24.17
$1.57B0.94574,606 shs671,247 shs
Nurix Therapeutics, Inc. stock logo
NRIX
Nurix Therapeutics
$16.05
+1.9%
$14.57
$4.22
$18.12
$774.12M2.17916,188 shs599,519 shs
Ten Starter Stocks For Beginners to Buy Now Cover

Just getting into the stock market? These 10 simple stocks can help beginning investors build long-term wealth without knowing options, technicals, or other advanced strategies.

Get This Free Report

Price Performance

Company1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year Performance
AnaptysBio, Inc. stock logo
ANAB
AnaptysBio
-1.96%-1.84%-11.70%-7.34%+25.37%
Crinetics Pharmaceuticals, Inc. stock logo
CRNX
Crinetics Pharmaceuticals
+4.21%-2.51%-1.95%+7.80%+110.27%
Heron Therapeutics, Inc. stock logo
HRTX
Heron Therapeutics
+4.32%+12.21%+47.89%+50.78%+244.64%
Kura Oncology, Inc. stock logo
KURA
Kura Oncology
+2.81%+0.09%+2.71%+0.71%+60.53%
Nurix Therapeutics, Inc. stock logo
NRIX
Nurix Therapeutics
+1.90%+5.80%+25.59%+20.31%+46.98%

MarketRank™

CompanyOverall ScoreAnalyst's OpinionShort Interest ScoreDividend StrengthESG ScoreNews and Social Media SentimentCompany OwnershipEarnings & Valuation
AnaptysBio, Inc. stock logo
ANAB
AnaptysBio
1.9035 of 5 stars
4.40.00.00.02.32.50.0
Crinetics Pharmaceuticals, Inc. stock logo
CRNX
Crinetics Pharmaceuticals
3.9416 of 5 stars
4.51.00.03.72.02.50.0
Heron Therapeutics, Inc. stock logo
HRTX
Heron Therapeutics
3.4597 of 5 stars
3.50.00.04.22.61.70.6
Kura Oncology, Inc. stock logo
KURA
Kura Oncology
3.2929 of 5 stars
3.41.00.04.72.80.80.0
Nurix Therapeutics, Inc. stock logo
NRIX
Nurix Therapeutics
1.645 of 5 stars
4.41.00.00.02.00.80.0

Analyst Ratings

CompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current Price
AnaptysBio, Inc. stock logo
ANAB
AnaptysBio
2.78
Moderate Buy$46.3897.59% Upside
Crinetics Pharmaceuticals, Inc. stock logo
CRNX
Crinetics Pharmaceuticals
2.92
Moderate Buy$60.9231.63% Upside
Heron Therapeutics, Inc. stock logo
HRTX
Heron Therapeutics
3.00
Buy$5.5042.49% Upside
Kura Oncology, Inc. stock logo
KURA
Kura Oncology
2.86
Moderate Buy$27.9431.84% Upside
Nurix Therapeutics, Inc. stock logo
NRIX
Nurix Therapeutics
2.88
Moderate Buy$21.8836.29% Upside

Current Analyst Ratings

Latest CRNX, HRTX, NRIX, KURA, and ANAB Analyst Ratings

DateCompanyBrokerageActionRatingPrice TargetDetails
5/23/2024
Crinetics Pharmaceuticals, Inc. stock logo
CRNX
Crinetics Pharmaceuticals
Robert W. Baird
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Boost Price TargetOutperform ➝ Outperform$52.00 ➝ $62.00
5/23/2024
Crinetics Pharmaceuticals, Inc. stock logo
CRNX
Crinetics Pharmaceuticals
Morgan Stanley
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Boost Price TargetOverweight ➝ Overweight$50.00 ➝ $70.00
5/23/2024
Crinetics Pharmaceuticals, Inc. stock logo
CRNX
Crinetics Pharmaceuticals
HC Wainwright
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Reiterated RatingBuy ➝ Buy$60.00 ➝ $60.00
5/16/2024
Heron Therapeutics, Inc. stock logo
HRTX
Heron Therapeutics
Needham & Company LLC
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Reiterated RatingBuy ➝ Buy$5.00
5/16/2024
Kura Oncology, Inc. stock logo
KURA
Kura Oncology
JMP Securities
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Reiterated RatingMarket Outperform ➝ Market Outperform$32.00
5/15/2024
Nurix Therapeutics, Inc. stock logo
NRIX
Nurix Therapeutics
Stifel Nicolaus
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Reiterated RatingBuy ➝ Buy$27.00
5/14/2024
Crinetics Pharmaceuticals, Inc. stock logo
CRNX
Crinetics Pharmaceuticals
Cantor Fitzgerald
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Reiterated RatingOverweight ➝ Overweight$65.00
5/14/2024
Kura Oncology, Inc. stock logo
KURA
Kura Oncology
HC Wainwright
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Reiterated RatingBuy ➝ Buy$32.00
5/14/2024
Nurix Therapeutics, Inc. stock logo
NRIX
Nurix Therapeutics
Needham & Company LLC
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Reiterated RatingBuy ➝ Buy$31.00
5/14/2024
Nurix Therapeutics, Inc. stock logo
NRIX
Nurix Therapeutics
Stephens
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Initiated CoverageOverweight$20.00
5/10/2024
AnaptysBio, Inc. stock logo
ANAB
AnaptysBio
Wedbush
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Reiterated RatingOutperform ➝ Outperform$34.00
(Data available from 6/4/2021 forward. View 10+ years of historical ratings with our analyst ratings screener.)

Sales & Book Value

CompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/Book
AnaptysBio, Inc. stock logo
ANAB
AnaptysBio
$17.16M37.37N/AN/A$3.32 per share7.07
Crinetics Pharmaceuticals, Inc. stock logo
CRNX
Crinetics Pharmaceuticals
$4.01M910.13N/AN/A$8.07 per share5.73
Heron Therapeutics, Inc. stock logo
HRTX
Heron Therapeutics
$127.04M4.58N/AN/A($0.23) per share-16.78
Kura Oncology, Inc. stock logo
KURA
Kura Oncology
N/AN/AN/AN/A$5.35 per shareN/A
Nurix Therapeutics, Inc. stock logo
NRIX
Nurix Therapeutics
$76.99M10.25N/AN/A$4.13 per share3.89

Profitability & Earnings

CompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings Date
AnaptysBio, Inc. stock logo
ANAB
AnaptysBio
-$163.62M-$6.14N/AN/AN/A-711.17%-161.40%-35.07%8/5/2024 (Estimated)
Crinetics Pharmaceuticals, Inc. stock logo
CRNX
Crinetics Pharmaceuticals
-$214.53M-$3.78N/AN/AN/A-4,223.27%-42.50%-36.96%8/13/2024 (Estimated)
Heron Therapeutics, Inc. stock logo
HRTX
Heron Therapeutics
-$110.56M-$0.61N/A386.00N/A-61.28%N/A-37.18%8/12/2024 (Estimated)
Kura Oncology, Inc. stock logo
KURA
Kura Oncology
-$152.63M-$2.17N/AN/AN/AN/A-37.52%-34.11%8/1/2024 (Estimated)
Nurix Therapeutics, Inc. stock logo
NRIX
Nurix Therapeutics
-$143.95M-$2.66N/AN/AN/A-178.93%-67.08%-43.62%7/11/2024 (Estimated)

Latest CRNX, HRTX, NRIX, KURA, and ANAB Earnings

DateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails
5/9/2024Q1 2024
AnaptysBio, Inc. stock logo
ANAB
AnaptysBio
-$1.54-$1.64-$0.10-$1.64$4.55 million$7.18 million
5/9/2024Q1 2024
Crinetics Pharmaceuticals, Inc. stock logo
CRNX
Crinetics Pharmaceuticals
-$0.84-$0.93-$0.09-$0.93$0.20 million$0.64 million    
5/7/2024Q1 2024
Heron Therapeutics, Inc. stock logo
HRTX
Heron Therapeutics
-$0.08-$0.02+$0.06-$0.02$32.50 million$34.67 million
5/2/2024Q1 2024
Kura Oncology, Inc. stock logo
KURA
Kura Oncology
-$0.56-$0.59-$0.03-$0.59N/AN/A    
4/10/2024Q1 2024
Nurix Therapeutics, Inc. stock logo
NRIX
Nurix Therapeutics
-$0.80-$0.76+$0.04-$0.76$14.58 million$16.59 million
3/12/2024Q4 2023
Heron Therapeutics, Inc. stock logo
HRTX
Heron Therapeutics
-$0.15-$0.07+$0.08-$0.07$30.98 million$34.23 million
3/11/2024Q4 2023
AnaptysBio, Inc. stock logo
ANAB
AnaptysBio
-$1.74-$1.59+$0.15-$1.59$3.28 million$9.01 million

Dividends

CompanyAnnual PayoutDividend Yield3-Year Dividend GrowthPayout RatioYears of Consecutive Growth
AnaptysBio, Inc. stock logo
ANAB
AnaptysBio
N/AN/AN/AN/AN/A
Crinetics Pharmaceuticals, Inc. stock logo
CRNX
Crinetics Pharmaceuticals
N/AN/AN/AN/AN/A
Heron Therapeutics, Inc. stock logo
HRTX
Heron Therapeutics
N/AN/AN/AN/AN/A
Kura Oncology, Inc. stock logo
KURA
Kura Oncology
N/AN/AN/AN/AN/A
Nurix Therapeutics, Inc. stock logo
NRIX
Nurix Therapeutics
N/AN/AN/AN/AN/A

Debt

CompanyDebt-to-Equity RatioCurrent RatioQuick Ratio
AnaptysBio, Inc. stock logo
ANAB
AnaptysBio
N/A
11.53
11.53
Crinetics Pharmaceuticals, Inc. stock logo
CRNX
Crinetics Pharmaceuticals
N/A
17.72
17.72
Heron Therapeutics, Inc. stock logo
HRTX
Heron Therapeutics
N/A
2.47
1.90
Kura Oncology, Inc. stock logo
KURA
Kura Oncology
0.02
16.67
16.67
Nurix Therapeutics, Inc. stock logo
NRIX
Nurix Therapeutics
N/A
2.86
2.86

Ownership

Institutional Ownership

CompanyInstitutional Ownership
AnaptysBio, Inc. stock logo
ANAB
AnaptysBio
N/A
Crinetics Pharmaceuticals, Inc. stock logo
CRNX
Crinetics Pharmaceuticals
98.51%
Heron Therapeutics, Inc. stock logo
HRTX
Heron Therapeutics
80.01%
Kura Oncology, Inc. stock logo
KURA
Kura Oncology
N/A
Nurix Therapeutics, Inc. stock logo
NRIX
Nurix Therapeutics
N/A

Miscellaneous

CompanyEmployeesShares OutstandingFree FloatOptionable
AnaptysBio, Inc. stock logo
ANAB
AnaptysBio
11727.32 million18.11 millionOptionable
Crinetics Pharmaceuticals, Inc. stock logo
CRNX
Crinetics Pharmaceuticals
29078.86 million74.13 millionOptionable
Heron Therapeutics, Inc. stock logo
HRTX
Heron Therapeutics
126150.65 million141.01 millionOptionable
Kura Oncology, Inc. stock logo
KURA
Kura Oncology
14276.18 million71.99 millionOptionable
Nurix Therapeutics, Inc. stock logo
NRIX
Nurix Therapeutics
28449.15 million44.33 millionOptionable

CRNX, HRTX, NRIX, KURA, and ANAB Headlines

Recent News About These Companies

Nurix Therapeutics (NASDAQ:NRIX) Trading Up 6.7%
Nurix Therapeutics Appoints Paula G. O'Connor, M.D.
Nurix Therapeutics Announces Board Chair Transition
Nurix Therapeutics, Inc. (NRIX)

New MarketBeat Followers Over Time

Media Sentiment Over Time

Top Headlines

All Headlines

Company Descriptions

AnaptysBio logo

AnaptysBio

NASDAQ:ANAB
AnaptysBio, Inc., a clinical-stage biotechnology company, focuses in delivering immunology therapeutics. Its products include Rosnilimab, an IgG1 antibody that targets PD-1+ T cells, resulting in their agonism or depletion, broadly impacting pathogenic drivers of autoimmune and inflammatory diseases; and ANB032, a non-depleting antibody that binds to the BTLA checkpoint receptor and inhibits activated T cell proliferation; ANB033, a novel anti-CD122 antagonist antibody that targets the shared common beta subunit of the receptors for IL-15 and IL-2; ANB101, a BDCA2 modulator antibody that specifically targets plasmacytoid dendritic cells (pDCs); and Imsidolimab, an antibody that inhibits the interleukin-36 receptor, which is in the Phase 3 development for the treatment of generalized pustular psoriasis. The company also focuses on developing various antibody programs that are advanced to preclinical and clinical milestones under its collaborations. It has a collaboration and license agreement with GlaxoSmithKline, Inc. The company was formerly known as Anaptys Biosciences, Inc. and changed its name to AnaptysBio, Inc. in July 2006. AnaptysBio, Inc. was incorporated in 2005 and is based in San Diego, California.
Crinetics Pharmaceuticals logo

Crinetics Pharmaceuticals

NASDAQ:CRNX
Crinetics Pharmaceuticals, Inc., a clinical-stage pharmaceutical company, focuses on the discovery, development, and commercialization of novel therapeutics for rare endocrine diseases and endocrine-related tumors. The company's lead product candidate is paltusotine, an oral selective nonpeptide somatostatin receptor type 2 agonist, which is in Phase 3 trial for the treatment of acromegaly; and Phase 2 trial for treating carcinoid syndrome associated with neuroendocrine tumors. It is also developing CRN04894, an investigational oral nonpeptide product candidate to antagonize the adrenocorticotrophic hormone (ACTH) receptor that has completed a Phase 1 study for the treatment of diseases caused by excess ACTH, including congenital adrenal hyperplasia and Cushing's disease. In addition, the company is developing antagonists of the parathyroid hormone (PTH) receptor for the treatment of primary hyperparathyroidism and humoral hypercalcemia of malignancy, and other diseases of excess PTH; identified investigational orally available somatostatin receptor type 3 targeted nonpeptide agonists for the treatment of autosomal dominant polycystic kidney disease; and developing thyroid-stimulating hormone receptor antagonists for the treatment of graves' disease and thyroid eye disease, as well as Oral GLP-1 and GIP nonpeptides for the treatment of diabetes and obesity. Crinetics Pharmaceuticals, Inc. was incorporated in 2008 and is headquartered in San Diego, California.
Heron Therapeutics logo

Heron Therapeutics

NASDAQ:HRTX
Heron Therapeutics, Inc., a commercial-stage biotechnology company, focuses on enhancing the lives of patients by developing and commercializing therapeutic that enhances medical care. The company's product candidates utilize its proprietary Biochronomer, a drug delivery technology, which delivers therapeutic levels of a range of short-acting pharmacological agents over a period from days to weeks with a single administration. It offers SUSTOL (granisetron), an extended-release injection for the prevention of acute and delayed nausea and vomiting associated with moderately emetogenic chemotherapy, or anthracycline and cyclophosphamide combination chemotherapy regimens; and CINVANTI, an intravenous formulation of aprepitant, a substance P/neurokinin-1 receptor antagonist for the prevention of acute and delayed nausea and vomiting associated with highly emetogenic cancer chemotherapy, as well as nausea and vomiting associated with moderately emetogenic cancer chemotherapy. The company is also developing ZYNRELEF, a dual-acting local anesthetic that delivers a fixed-dose combination of the local anesthetic bupivacaine and a low dose of the nonsteroidal anti-inflammatory drug meloxicam; and APONVIE, an intravenous formulation of a substance P/neurokinin-1 receptor antagonist indicated for the prevention of postoperative nausea and vomiting in adults. The company was formerly known as A.P. Pharma, Inc. and changed its name to Heron Therapeutics, Inc. in January 2014. Heron Therapeutics, Inc. was founded in 1983 and is headquartered in San Diego, California.
Kura Oncology logo

Kura Oncology

NASDAQ:KURA
Kura Oncology, Inc., a clinical-stage biopharmaceutical company, develops medicines for the treatment of cancer. The company's pipeline consists of small molecule product candidates that target cancer. Its lead product candidates are ziftomenib, an orally bioavailable small molecule inhibitor of the menin-KMT2A interaction for the treatment of genetically defined subsets of acute leukemias, including acute myeloid leukemia and acute lymphoblastic leukemia; tipifarnib, an orally bioavailable farnesyl transferase inhibitor combination with alpelisib for patients with PIK3CA-dependent HNSCC; and KO-2806, a farnesyl transferase inhibitor for the treatment of solid tumors. It has a clinical collaboration with Novartis Pharma AG to evaluate the combination of tipifarnib and alpelisib in patients with head and neck squamous cell carcinoma whose tumors have HRAS overexpression and/or PIK3CA mutation and/or amplification. The company was founded in 2014 and is headquartered in San Diego, California.
Nurix Therapeutics logo

Nurix Therapeutics

NASDAQ:NRIX
Nurix Therapeutics, Inc., a clinical stage biopharmaceutical company, focuses on the discovery, development, and commercialization of small molecule and cell therapies for the treatment of cancer, inflammatory conditions, and other diseases. The company develops NX-2127, an orally bioavailable Bruton's tyrosine kinase (BTK) degrader for the treatment of relapsed or refractory B-cell malignancies; NX-5948, an orally bioavailable BTK degrader for the treatment of relapsed or refractory B-cell malignancies and autoimmune diseases; and NX-1607, an orally bioavailable Casitas B-lineage lymphoma proto-oncogene-B (CBL-B) inhibitor for immuno-oncology indications. It is also developing NX-0479/GS-6791, a IRAK4 degrader for the treatment of rheumatoid arthritis and other inflammatory diseases. The company has a strategic collaboration agreement with Gilead Sciences, Inc., Sanofi S.A., and Seagen Inc. co-development and co-commercialization for multiple drug candidates. The company was formerly known as Nurix Inc. and changed its name to Nurix Therapeutics, Inc. in October 2018. Nurix Therapeutics, Inc. was incorporated in 2009 and is headquartered in San Francisco, California.